skip to main content
Close Icon We use cookies to improve your website experience.  To learn about our use of cookies and how you can manage your cookie settings, please see our Cookie Policy.  By continuing to use the website, you consent to our use of cookies.
Global Search Configuration

Introduction

BRAND NEW: Our pipeline report now contains an interactive early-phase forecast model and a  chapter on early-phase opportunities within asthma – exclusive content you’ll only find at Datamonitor Healthcare.

Severe asthma remains a significant cause of mortality and morbidity and a portion of patients remain inadequately treated. Biologics in the pipeline for asthma aiming to treat this patient population. Datamonitor Healthcare has provided an in-depth analysis of pipeline products in the US, Japan and five major EU markets, including new clinical data and an evaluation of clinical and commercial drug attributes.

Click here to download your free Table of Contents >>
Click here to download your free Sample Pages >>

How will our asthma pipeline report benefit you?

  • Target unmet needs
    Understand which populations in asthma are inadequately treated and how late-stage therapies will target these patient groups, enabling you to identify where there is still room for opportunities and what needs are currently being overlooked.
  • Identify investment opportunities
    Explore the future developments in the treatment of asthma, understanding how once-daily fixed-dose inhalers such as Breo will change therapy and how asthma therapy will progress, allowing you to identify what therapies you should be investing in to gain potential commercial success within the market.
  • Gain competitive overview
    Understand how biologics will position themselves within the market and compete against each other by comparing their clinical and commercial attributes, allowing you to benchmark your product against that with the most potential for success.
  • Identify early-phase opportunities
    Access our exclusive interactive 20-year early-phase forecast model with clearly identified opportunities to assist in your decision-making.

Key questions answered:

  • What pipeline therapies are set to compete successfully in the asthma market?
  • How successful has clinical development program been for biologics so far?
  • How will targeted therapies fit into the future of treatment within the market?
http://http//www.datamonitorhealthcare.com/files/2014/10/Asthma-Pipeline-10.10.2014.pdf

Read also

  • Datamonitor Healthcare: data analysis and insight

    mHealth and Research in Oncology

    The World Health Organization defines mobile health (mHealth) as a “medical and public health practice supported by mobile devices, such as mobile phones, patient monitoring devices, personal digital assistants, and other wireless devices”. In the last decade, the health sector has seen a substantial rise in the number of mHealth apps, many of which are designed to assist users in weight reduction and diabetes management. In 2016, there were 79,000 apps available in the Health & Fitness category in the Google and Apple stores. However, the implementation of mHealth in oncology is lagging, and there are comparatively few available apps. There is a need for the development of more mHealth apps in oncology settings considering the increasing disease burden and potential clinical benefit. 

  • Datamonitor Healthcare: data analysis and insight, Biomedtra...

    Gene therapy manufacturers

    Given the transformative nature of regenerative medicines, which can yield greatly improved patient responses, meet unmet need, and now exist as viable products on the market, cell and gene therapeutics developers over the past several years have been drawing deal attention, not only through collaborative partnerships, but also as acquisition targets.

  • Biomedtracker: see the drug development process through anal...

    Deconstructing the KRAS+ market opportunity

    By Daniel Chancellor

    With arguably the standout data from the 2019 American Society for Clinical Oncology (ASCO) annual meeting, Amgen has become the first company to show that KRAS, beyond its role as an oncogene, is also a viable drug target

    Topics BioPharmaceutical Drug Review

;

Next steps

Getting a demo tailored to your needs is the best way to see how our solutions will help you gain an advantage.

Request live demo now:

Our team is always happy to hear from you. Please call us at:

  • US Toll-Free  : +1 888 670 8900
  • US Toll           : +1 908 547 2200
  • UK & Europe : +44 (20) 337 73737
  • Australia        : +61 2 8705 6907
  • Japan              : +81 3 6273 4260

Or please submit your inquiry via the form so that we can provide you the best possible customer service.

Have an immediate and specific information need?

Browse and buy from 1000s of analysis and research reports now: